Docetaxel is the guideline-recommended first-line chemotherapy in men with castration-resistant prostate cancer (CRPC). Despite its proven survival benefit, however, all patients will progress after a mean interval of six to eight months. Recently, the FDA approved cabazitaxel and abiraterone acetate as effective second-line treatment options in this clinical scenario. By comparison with mitoxantrone, cabazitaxel improves progression-free survival, overall survival, time to prostate surface antigen (PSA) progression and time to metastatic progression. On the other hand, cabazitaxel (Sanofi) is asscociated with a significantly higher frequency of grade 3 and 4 haematotoxic and gastrointestinal side effects than mitoxantrone. In experienced hands, and with the use of proactive therapeutic measures -such as weekly monitoring, adequate patient counselling and appropriate application of the guidelines on management and prophylaxis of neutropenia and diarrhoea -all side effects can be handled easily without harming the patient, as has been shown recently by the analysis of the results of the German and European compassionate use programmes. Cabazitaxel is one of the key components in the management of disease progression after docetaxel, and might be of benefit in men with high metastatic burden, rapid PSA doubling time and minimal side effects during first-line docetaxel therapy.
CRPC who had progressed after docetaxel-based chemotherapy. 5 Eighty-seven percent of patients had received one docetaxel-based cytotoxic regime, and 12 % and 2 % of patients had received two and three docetaxel-based cytotoxic regimes, respectively. About 25 % of patients had received three to six cycles of docetaxel and prednisone, while 30 % and ~20 % had received six to nine cycles and ≥10 cycles of treatment, respectively.
Patients were randomised to receive either cabazitaxel at 25 mg/m 2 intravenously over one hour, or mitoxantrone at 12 mg/m 2 over 15-30 minutes, once every 21 days. All patients received prednisone 5 mg twice daily throughout the treatment period.
The primary study goal was improvement of overall survival (OS).
Secondary study endpoints were progression-free survival (PFS), prostate surface antigen (PSA) response rate, objective remission rate and safety. It was intended that patients should receive at least six cycles of treatment, ideally up to 10 cycles should be applied.
Oncological Results
After a mean follow-up of 12.8 months a significant survival benefit of 2.4 months was documented for the cabazitaxel group: mean survival increased from 12.7 months to 15.1 months (p<0.0001). However, this was only achieved for patients who received a cumulative docetaxel dose of at least 225 mg/m2, which might have been because the PSA increase in patients with a cumulative dose <225 mg/m 2 was due to a PSA flare-up phenomenon, and not due to progression of taxane-resistant prostate cancer. In fact, patients with a cumulative dose <225 mg/m 2 were only excluded from the ongoing trial by a subsequent protocol amendment. A total of 59 patients with a cumulative docetaxel dose <225 mg/m 2 had been recruited prior to the amendment. 
Safety Profile
By comparison with mitoxantrone, application of cabazitaxel was associated with a significantly higher frequency of treatmentassociated side effects.
Haematotoxicity was the most frequent side effect, and grade 3-4 neutropenia, leukopenia and anaemia occurred in 82 %, 68 % and 11 % of patients, respectively. In the mitoxantrone arm, neutropenia, leukopenia and anaemia developed in 58 %, 42 % and 5 %, respectively. Febrile neutropenia developed in 8 % of patients in the cabazitaxel versus 1 % of patients in the mitoxantrone group.
Neutropenia was observed significantly more often in men >65 years than in younger men (24.2 % versus 17.6 %). There was also a significantly increased risk of neutropenia in men treated in Europe and the USA when compared to men treated elsewhere, with frequencies of 25.7 % for North America, 16.1 % for Europe and 35.1 % for other.
Grades 3 and 4 diarrhoea represented the most frequent non-haematological event in 6 % and 1 % of the patients receiving cabazitaxel and mitoxantrone, respectively. Diarrhoea developed significantly more often in patients aged >75 years than in younger patients (55.7 % versus 44.5 %), and also more frequently in patients with previous radiation therapy of the prostate (50 % versus 41.4 % without radiation).
Due to the high frequency of significant side effects, the treatment-associated mortality rate was also higher in the cabazitaxel group (5 % versus 2 %).
Commentary
Besides abiraterone acetate, cabazitaxel represents a guidelinerecommended, evidence-based treatment option with a significant survival benefit in patients with progressive, metastatic CRPC following docetaxel-based chemotherapy. 16 Based on data from the TROPIC trial, cabazitaxel should only be considered in patients who previously have Cabazitaxel in the Management of Metastatic Castration-resistant Prostate Cancer It is not yet known, which sequence -cabazitaxel followed by abiraterone or vice versa -might result in better long-term results.
Neither is it yet known if there are differences in the response rates of the two drugs depending on the extent and location of metastases.
There are only results from a first study analysing the response of docetaxel following abiraterone acetate, which showed a poorer response rate for docetaxel and suggested a cross resistance between both drugs. 18 However, there are no data available with regard to response rates of cabazitaxel followed by abiraterone acetate and vice versa. The impression from a first case-control study and a head-to-head comparison of cabazitaxel and abiraterone acetate in a group of 71 patients has demonstrated longer PFS times and higher response rates for cabazitaxel. 19 However, these data have to be substantiated by further analysis in a larger patient cohort.
Currently, there is no evidence in favour of one or the other drug, and patients have to be counselled individually on a subjective interpretation of the previous course of their disease.
To this author it seems that the response to previous docetaxel chemotherapy, side effects experienced during docetaxel therapy, comorbidities and extent of disease are major criteria for stratifying patients for cabazitaxel or abiraterone acetate as first choice for treating progression of CRPC after docetaxel therapy. n
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